Abstract
e18536Background: TP53 mutated or del(17p) chronic lymphocytic leukemia (CLL) has high incidence of transformation to high-grade lymphoma. Ibrutinib is approved as first line agent for these high r...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
